Presentation on theme: "Tiziano Barbui MD Ospedale Papa Giovanni XXIII Bergamo, Italy"— Presentation transcript:
1 Tiziano Barbui MD Ospedale Papa Giovanni XXIII Bergamo, Italy Emerging JAK Inhibitors in Myelofibrosis: Determining the Right Agent for the Right Patient.(Madrid) How to use prognosis assessment criteria for MF management in the clinical practiceTiziano Barbui MDOspedale Papa Giovanni XXIIIBergamo, Italy
8 Incidence of AML OS Incidence of MF Survival, Leukemic Transformation and Fibrotic Progression in Essential Thrombocythemia are significantly influenced by Accurate Morphologic DiagnosisIncidence of AMLOSIncidence of MFBarbui et al, Leukemia 2013Barbui et al, J Clin Oncol Aug 10;29(23):
23 Myelofibrosis: Prognosis assessment in clinical practice PMF risk stratification is based on IPSS and DIPSS, but cytogenetics and transfusional status may be a compendiumNovel prognostic variables deserve further investigations on a large scale
Your consent to our cookies if you continue to use this website.